Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has enhanced its U.S. footprint by inaugurating a new office in Cambridge, Massachusetts. This strategic move positions the company closer to key biotechnology and pharmaceutical enterprises in the Boston area, facilitating stronger partnerships and providing essential local support for clinical trials in the region.
The Cambridge office will bolster IAG’s efforts in various therapeutic areas, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic and metabolic diseases. By establishing a presence in this life-sciences hub, IAG aims to work more intimately with sponsors and contract research organizations conducting Phase I–III clinical trials and imaging-intensive development programs. In addition, the company intends to generate local employment opportunities, planning to hire in clinical imaging operations, data science, regulatory support, and business development over the next one to two years.
The new office will also enhance IAG’s comprehensive imaging services, which cover clinical trial design consultation, imaging protocol optimization, centralized image analysis, and delivery of regulatory-compliant data. The company’s integration into the Boston life-sciences ecosystem is expected to foster improved collaboration with biotechnology firms, pharmaceutical organizations, academic institutions, and clinical research centers.
Globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region, collaborating with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. The company’s global operations are designed to ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). The company aids pharmaceutical, biotechnology, and medical technology companies by providing imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform leverages AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and offers real-time oversight of clinical trials to support its diverse work in oncology, inflammatory, musculoskeletal, cardiometabolic, and rare disease indications.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.